JNJ Finance Insights | Art Argentum

2026-07-21 22:10 UTC

Rebound in Chipmakers Gathers Pace | The Close 7/21/2026

Bloomberg Television panel_debate

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Kayne Anderson Rudnick Portfolio Manager Julie Biel, Vanguard Head of Product & Portfolio Strategy Rachel Aguirre, Novartis International CEO Vas Narasimhan, Amazon Business Director & Head of Value & Selection Daniel Silverfield, Raymond James Advisory Solutions Market Strategy Head Matt Orton, JP Morgan Asset Management Global Alternatives Strategist Aaron Mulvihill, Lossdog Founder & Co-CEO Tom Sosnoff, Coldwell Banker Affiliates President Mary Lee Blaylock, & Cox Automotive Industry Insights Director Stephanie Valdez Streaty. Chapters: 00:00:00 Bloomberg The Close 00:04:05 Kayne Anderson Rudnick on Chips, Software & Market Breadth 00:09:45 Vanguard's AI Outlook: Why Value Stocks Could Benefit Most 00:14:13 Novar…

15m—20m

Novartis CEO Vas Narasimhan expresses confidence in the growth potential of cancer drugs Kisimta and Kisqali, projected to achieve peak sales of $6 billion and $10 billion respectively.

The company is addressing the loss of patent protection on several drugs while relying on a new pipeline to sustain growth in the range of 5 to 6 percent through the end of the decade.

Narasimhan notes that Novartis has incorporated the Most Favored Nation agreements with the US government into its pricing strategies for eight target countries.

He cautions that pricing policies in Europe may lead to reduced access to new medicines, as only 60% of new medicines are currently launched in a timely manner in the region.

Our interpretation: The challenges posed by patent expirations and evolving pricing regulations could pressure Novartis's market positioning, necessitating strategic adjustments to maintain growth and access in competitive environments.

2026-07-06 20:46 UTC

Nasdaq Reclaims Key Level; Howmet, Johnson & Johnson, Sandisk In Focus | Stock Market Today

Investor's Business Daily podcast_discussion

Ken Shreve and Ed Carson walk through Monday's post-holiday market action and discuss key stocks to watch in Stock Market Today. Stock Market Today: July 6, 2026 Hosts: Ken Shreve and Ed Carson Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: https://www.investors.com Like us on Facebook: https://www.facebook.com/investorsbusinessdaily Follow us on Twitter: https://twitter.com/IBDinvestors Follow us on Instagram: https://www.instagram.com/investorsbusinessdaily/ Follow us on StockTwits: https://stocktwits.com/InvestorsBusinessdaily Follow us on LinkedIn: https://www.linkedin.com/company/investors-business-daily Follow us on TikTok: https://www.tiktok.com/@ibdinvestors Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial an…

0s—5m

The NASDAQ composite increased by 1.1%, recovering above the 50-day moving average following a previous distribution day.

The VanEck Semiconductor Index (SMH) rose approximately 2%, despite closing slightly below its session highs.

The S&P 500 closed above the 7500 level, reflecting a gain of 0.71% for the day.

The Dow Jones Industrial Average lagged, with a modest increase of 0.10%, impacted by declines in the healthcare sector.

The NASDAQ has experienced volatility, particularly in tech stocks, with notable fluctuations in the semiconductor and software sectors.

The discussion emphasized the necessity of breaking above last week's highs to indicate a potential reversal of the current downtrend.

Our interpretation: The market's recovery in the NASDAQ and semiconductor sectors suggests a cautious optimism, but the lack of strong buying conviction indicates that sustained upward momentum may depend on overcoming key resistance levels.

15m—20m

Many areas of the medical sector, including biotechs and traditional drug makers, are performing well, indicating a diverse range of investment opportunities.

Howmet Aerospace (HWM), a major Boeing supplier, is currently sitting just below a buy point of 280.74, suggesting potential for upward movement if it surpasses this level.

Johnson & Johnson, a Dow component, has recently experienced a breakout, although its growth is characterized as relatively meager, with single-digit growth expectations.

While defensive stocks like Johnson & Johnson may not tumble significantly in a market downturn, their ability to rally could be limited if the market experiences a strong upswing.

Howmet Aerospace has maintained a high composite rating due to its strong fundamentals and earning stability, making it a notable leader in the aerospace sector.

Our interpretation: The current performance of the medical sector, alongside the stability of companies like Howmet Aerospace, suggests that defensive positioning in portfolios may be prudent, especially in light of potential market shifts.

20m—25m

Growth investors have been focusing on chips and AI, while the overall market remains generally positive despite some unease.

Defensive stocks, such as Johnson & Johnson, can still achieve gains in the current market environment, but being defensive does not guarantee safety.

Johnson & Johnson is noted for its low earnings stability rank and consistent earnings track record, along with a decent dividend yield.

Sandisk appears vulnerable as it approaches the 50-day moving average after a significant drop below the 21-day line.

Sandisk's earnings have been exceptionally high, reflecting strong performance despite recent market fluctuations.

Our interpretation: The current market dynamics suggest that while defensive stocks like Johnson & Johnson may provide stability, they could lag if the market shifts towards growth sectors, particularly if AI stocks rebound, potentially leading to a reallocation of capital away from defensive names.